Donorplasma

Donorplasma refers to human plasma collected from volunteers for medical use. It is obtained primarily by plasmapheresis or, less commonly, as part of whole-blood donations. Donorplasma serves as a transfusion product and as the raw material for plasma-derived medicines. The term is used in clinical and regulatory contexts to distinguish donor plasma from synthetic substitutes and from plasma fractions recovered after processing.

Collection and safety: Donorplasma donors undergo health screening and infectious-disease testing. The plasma is processed to remove cellular components, and many programs apply pathogen-inactivation steps. In plasmapheresis, plasma is separated and the cellular components are returned to the donor; a typical donation yields about 600 mL, with procedures designed to minimize donor risk. Stored plasma is kept as fresh-frozen plasma at -18 C or colder, and thawed plasma has a limited shelf life.

Uses and products: Donorplasma is transfused for coagulation disorders, liver disease, trauma, and other bleeding conditions. It is also the starting material for plasma-derived products such as albumin, immunoglobulins, and clotting factors, which are prepared through fractionation. Some patients receive plasma during plasma exchange therapies. Distribution and traceability are regulated to ensure safety from donor to recipient.

Regulation and ethics: Regulatory agencies in many countries oversee donor recruitment, testing, storage, labeling, and distribution. Standards from organizations such as the FDA, EMA, and AABB promote safety and quality. Ethical considerations emphasize voluntary, non-remunerated donation and donor privacy, while ongoing monitoring for adverse reactions protects both donors and recipients.